title: P53 oncoprotein expression and gene mutations in some keratoacanthomas.
abstract: OBJECTIVE
  To analyze the relationship of p53 oncoprotein overexpression in most keratoacanthomas (KAs) with gene mutations.
  
  
  METHODS
  Expression of p53 oncoprotein in immunohistochemical staining and its correlation to gene mutations in DNA extracted from KAs and tested in single-strand conformational polymorphism (SSCP) analysis and direct sequencing.
  
  
  METHODS
  A micrographic surgery unit and a dermatopathology unit at a university medical center.
  
  
  METHODS
  Sixteen formalin-fixed, paraffin-embedded skin biopsy specimens were retrieved from dermatopathology archives. Biopsies were performed to establish the diagnosis of KA before surgical treatment.
  
  
  METHODS
  Intensity of staining in immunohistochemical testing for p53 oncoprotein expression and sequencing of gene mutations.
  
  
  RESULTS
  Immunohistochemical staining of 16 KA specimens detected p53 oncoprotein in 15 (94%), distributed as strong in 4 (25%), moderate in 2 (12%) mild in 9 (56%), and negative in 1 (6%), compared with control specimens. Specimens were screened by SSCP for mutations in the p53 gene, and 1 specimen showed a potential mutation in exon 7. Direct sequencing of the samples revealed 2 point mutations. One specimen showed a change of G:A for A:G in codon 146 of exon 5, predicting an amino acid substitution of tryptophan for a stop codon. Another specimen revealed a change of T:A for A:T in codon 234 of exon 7, predicting an amino acid substitution of tyrosine for asparagine.
  
  
  CONCLUSIONS
  Ninety-four percent of KA specimens evaluated had detectable p53 oncoprotein. This protein was associated with a point mutation in the p53 gene in 2 of 16 KAs evaluated. In a small fraction of KAs, overexpression of p53 oncoprotein may be associated with point mutations in the p53 gene.
authors.affiliation: Department of Dermatology, Columbia University, College of Physicians and Surgeons, St Luke's-Roosevelt Hospital Center, New York, USA.
authors.forename: M I
authors.initials: MI
authors.lastname: Perez
authors.forename: P
authors.initials: P
authors.lastname: Robins
authors.forename: S
authors.initials: S
authors.lastname: Biria
authors.forename: J
authors.initials: J
authors.lastname: Roco
authors.forename: E
authors.initials: E
authors.lastname: Siegel
authors.forename: A
authors.initials: A
authors.lastname: Pellicer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004252:DNA Mutational Analysis; D005786:Gene Expression Regulation / Q000235:genetics*; D006801:Humans; D007636:Keratoacanthoma / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D009154:Mutation; D018807:Polymorphism, Single-Stranded Conformational; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D016159:Tumor Suppressor Protein p53